EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY 4.0

Long term survival in adult osteosarcoma patients treated with a two-drug regimen: Final results of the OSAD93 phase II study of the FSG-GETO

Jean-Yves Blay, Nicolas Penel, Maud Toulmonde, Thibaud Valentin, Loic Chaigneau, Maria Rios, Esma Saada-Bouzid, Nelly Firmin, Francois Bertucci, Perrine Marec-Berard, Isabelle Ray-Coquard, Cyril Lervat und 11 weitere

European Journal of Cancer · 2024

DOI: 10.1016/j.ejca.2024.114228 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift European Journal of Cancer, 2024. Verfasst von Jean-Yves Blay und 22 weiteren Autor:innen. Beteiligte Einrichtung: Centre Léon Bérard, CRCL, Unicancer, Lyon Unicancer & UCBL1, Lyon, France. Electronic address: jean-yves.blay@lyon.unicancer.fr. Hauptthemen laut MEDLINE: Osteosarcoma, Antineoplastic Combined Chemotherapy Protocols, Bone Neoplasms, Ifosfamide. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Network for Rare Adult Solid Cancers, LabEx DEvweCAN, INCa.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OsteosarcomaAntineoplastic Combined Chemotherapy ProtocolsBone NeoplasmsIfosfamideHumansAdultMaleFemaleMiddle AgedYoung AdultAdolescentNeoadjuvant TherapyCisplatinDoxorubicinDisease-Free SurvivalFollow-Up Studies

Stichwörter der Autor:innen

AnthracuyclinsCDDPHigh gradeIfosfamideOsteogenic sarcomaRare cancersReference centersSurvival

Substanzen

IfosfamideCisplatinDoxorubicin

Autor:innen und Institutionen

  • Centre Léon Bérard, CRCL, Unicancer, Lyon Unicancer & UCBL1, Lyon, France. Electronic address: jean-yves.blay@lyon.unicancer.fr.
  • Centre Oscar Lambret, Lille, France.
  • Institut Bergonié, Bordeaux, France.
  • Institut Claudius Regaud, IUCT Oncopole, Toulouse, France.
  • CHU, Besançon, France.
  • Centre Alexis Vautrin, Nancy, France.

Förderung

  • European Network for Rare Adult Solid Cancers
  • LabEx DEvweCAN
  • INCa
  • Ligue Contre le Cancer
  • European Commission

Zitieren

APA

Blay, J. Y., Penel, N., Toulmonde, M., Valentin, T., Chaigneau, L., Rios, M., Saada-Bouzid, E., Firmin, N., Bertucci, F., Marec-Berard, P., Ray-Coquard, I., Lervat, C., Rolland, F., Thyss, A., Conroy, T., Brahmi, M., Dufresne, A., Merrouche, Y., Brunat-Mentigny, M., …, & French Sarcoma Group (2024). Long term survival in adult osteosarcoma patients treated with a two-drug regimen: Final results of the OSAD93 phase II study of the FSG-GETO. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2024.114228

Vancouver

Blay JY, Penel N, Toulmonde M, Valentin T, Chaigneau L, Rios M, et al. Long term survival in adult osteosarcoma patients treated with a two-drug regimen: Final results of the OSAD93 phase II study of the FSG-GETO. European Journal of Cancer. 2024. doi:10.1016/j.ejca.2024.114228

BibTeX
@article{Blay2024,
  author = {Blay, Jean-Yves and Penel, Nicolas and Toulmonde, Maud and Valentin, Thibaud and Chaigneau, Loic and Rios, Maria and Saada-Bouzid, Esma and Firmin, Nelly and Bertucci, Francois and Marec-Berard, Perrine and Ray-Coquard, Isabelle and Lervat, Cyril and Rolland, Frederic and Thyss, Antoine and Conroy, Thierry and Brahmi, Mehdi and Dufresne, Armelle and Merrouche, Yacine and Brunat-Mentigny, Maud and Biron, Pierre and Bompas, Emmanuelle and Perol, David and French Sarcoma Group, French Sarcoma Group},
  title = {Long term survival in adult osteosarcoma patients treated with a two-drug regimen: Final results of the OSAD93 phase II study of the FSG-GETO},
  journal = {European Journal of Cancer},
  year = {2024},
  doi = {10.1016/j.ejca.2024.114228}
}
Kostenlos starten →